Company Overview - Scinai Immunotherapeutics Ltd. is a biopharmaceutical company listed on Nasdaq (SCNI) with two main business units: one focused on the in-house development of inflammation and immunology (I&I) biological therapeutic products, and the other serving as a boutique CDMO for biological drug development and clinical trial services [4]. Key Appointments - Prof. Michael Schön has joined Scinai's Scientific Advisory Board, bringing extensive expertise in dermatology, particularly in chronic inflammatory skin diseases such as psoriasis and atopic dermatitis. His background includes over 440 scientific publications and significant experience in drug development [3]. - Dr. Jonathan Sadeh has been appointed as Chief Scientific Officer and Chief Medical Officer of Bausch Health, marking a notable change within Scinai's advisory team [3]. Innovation and Pipeline - Scinai is developing a pipeline of innovative nanosized VHH antibodies (nanoAbs) aimed at addressing diseases with significant unmet medical needs. The company emphasizes the potential of its targeted immunological therapeutic approaches in precision inflammation medicine [3][4].
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board